In the landmark Amgen v. Sanofi case (previously covered here), the Supreme Court affirmed that patent claims drawn to a genus of ...

where diverse natural CDRs are combined into an antibody framework 11, using only CDR-encoding gene fragments originating from sequences formed and “proofread” in vivo. Such proofread peptide ...

Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

The top-line results of the APOLLOE4 trial showed that valitramiprosate (ALZ-801) was unable to slow down cognitive decline ...

Since then, we have demonstrated notable platform improvements progressing from single CDR design to designing antibodies to targets with no known binders. These capabilities were clearly ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

Sabirnetug is the first humanized monoclonal antibody to demonstrate in AD patients ... Clinical Dementia Rating – Sum of Boxes scale (CDR-SB), ADAS-Cog13, ADCS-ADL and various AD biomarkers.

And then probably an Eric question, iADRS versus CDR Sum of Boxes, what’s the difference in your mind is I think every antibody that’s worked and has measured both has hit for both.